Clinical Profile and Features of Cardionephroprotective Therapy in Patients With Hypertensive Form of Chronic Glomerulonephritis

Abstract

The aim of the work was to evaluate the clinical profile of patients and the frequency of cardionephroprotective therapy in chronic glomerulonephritis (CGN) with hypertensive form (GF), the presence of chronic kidney disease (CKD) and associated clinical conditions. Material and methods. Patients with HF CGN, 102, men – 52, women – 50, (55,0 ± 11,84) years, and stage III EAG, 98, men – 45, women – 53, (64,45 ± 12,1) years, were examined, the diagnosis was verified in the Tver Region Regional Clinical Hospital. Results. Differences in the frequency of associated clinical conditions, stages of CKD and the administration of hypotensive, lipid-lowering and antiplatelet drugs were revealed between patients with HF CGN and EAG. Conclusions. The clinical profile of patients with GF CGN consists of stage 3b–4–5 CKD, CVB, DM, the clinical profile of EAG patients includes stage 1–2–3a CKD, CVB, DM, CHF and CHD. Cardionephroprotective therapy in patients with GF CGN consists in the early inclusion of lipid-lowering and antiplatelet drugs in therapy before the appearance of stage 3b CKD, CVB and always in the presence of DM.